Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.

摘要: Paclitaxel (PTX) has shown pleiotropic immunologic effects on the tumor microenvironment, and nanomicelle emerged as a promising strategy for PTX delivery. However, detailed mechanisms remain to be fully elucidated. Meanwhile, immunogenic cell death (ICD) is an effective approach activate immune system. This study investigated ICD effect of how affected immune-activation ability PTX. Methods: The were identified via expression markers vaccine experiment. Tumor size overall survival in multiple animal models with treatment monitored evaluate antitumor effects. PTX-induced immunity determined by detecting gene related ER stress analyzing profile after treatment. Results: We revealed immune-regulation mechanism inducing ICD, which can promote antigen presentation dendritic cells (DCs) immunity. Notably, encapsulation protected activation, hampered system impairment caused chemotherapy. Compared traditional formulations, low dose nanomicelle-encapsulated (nano-PTX) induced immune-dependent control, increased infiltration function both T DCs within tumors. this was highly expressed PD-1 tumor-infiltrating CD8+ upregulated PD-L1 nano-PTX Combination therapy antibodies elicited cell-dependent remarkably improved therapeutic efficacy. Conclusions: Our results provide systemic insights into induce acts inducer endogenous vaccines through effects, also provides experimental basis clinical combination antibodies.